Table 5 Medians, interquartile ranges and p-values of the primary and secondary outcomes
Outcomes | Subdomain (questionnaire) | T0a | T1a | Ca | P-value (Wilcoxon test) | Effect Size | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
N | Median (IQR) | N | Median (IQR) | N | Median (IQR) | C-T1 | T0-T1 | C-T1 | T0-T1 | ||
Self-management knowledge and behaviour | Total Score (PIHb) | 15 | 88.0 (81.0–92.0) | 15 | 88.0 (81.0–94.0) | 32 | 85.5 (80.0–93.0) | 0.54 | 0.41 | 0.20 | 0.24 |
Self-management knowledge and behaviour | Knowledge and coping (PIHb) | 15 | 51.0 (41.0–53.0) | 15 | 51.0 (45.0–55.0) | 33 | 47.0 (42.0–54.5) | 0.47 | 0.43 | 0.23 | 0.27 |
Self-management knowledge and behaviour | Recognition and management of symptoms, adherence to treatment (PIHb) | 15 | 38.0 (36.0–40.0) | 15 | 38.0 (36.0–40.0) | 32 | 38.5 (36.0–40.0) | 0.89 | 0.69 | 0.18 | 0.09 |
Quality of Life | General quality of life (WHOQol-BREFb) | 16 | 4.0 (3.0–4.0) | 16 | 4.0 (3.0–4.0) | 32 | 4.0 (3.0–4.0) | 0.73 | 0.56 | 0.20 | 0.22 |
Quality of Life | Satisfaction with health (WHOQol-BREFb) | 16 | 3.0 (2.0–4.0) | 16 | 3.5 (3.0–4.0) | 33 | 4.0 (3.0–4.0) | 0.27 | 0.40 | − 0.31 | 0.11 |
Quality of Life | Role limitations due to physical health problems (SF-36b) | 15 | 0.0 (0.0–50.0) | 15 | 75.0 (0.0–100.0) | 30 | 87.5 (0.0–100.0) | 0.78 | 0.02 | − 0.11 | 0.78 |
Quality of Life | Role limitations due to emotional problems (SF-36b) | 14 | 100.0 (0.25–100.0) | 15 | 100.0 (50.00–100.0) | 29 | 100.0 (66.7–100.0) | 0.55 | 0.73 | −  0.17 | 0.14 |
Quality of Life | Vitality (SF-36b) | 16 | 50.0 (26.3–58.8) | 16 | 32.5 (25.8–52.5) | 32 | 42.5 (25.0–53.8) | 0.58 | 0.03 | − 0.14 | −0.41 |
Quality of Life | General mental health (SF-36b) | 16 | 75.5 (61.5–88.0) | 16 | 84.0 (70.5–92.0) | 32 | 87.5 (64.0–92.0) | 0.75 | 0.27 | 0.11 | 0.27 |
Self-efficacy | Total score (SECD6b) | 16 | 5.3 (3.2–7.2) | 16 | 5.3 (2.8–7.6) | 30 | 5.6 (3.8–7.3) | 0.94 | 0.32 | −0.04 | 0.20 |
Self-efficacy | VAS - healthb | 16 | 60.1 (32.6–81.1) | 16 | 66.9 (50.7–79.8) | 32 | 70.5 (53.8–80.6) | 0.70 | 0.25 | − 0.13 | 0.31 |
Self-efficacy | VAS -painb | 16 | 8.3 (2.5–36.0) | 16 | 3,6 (0.4–25.7) | 33 | 2.9 (0.7–14.0) | 0.99 | 0.90 | 0.05 | 0.20 |
Self-efficacy | VAS - fatigueb | 16 | 57.2 (9.4–74.5) | 16 | 25.7 (19.6–65.5) | 33 | 43.9 (8.6–61.9) | 0.82 | 0.45 | − 0.08 | 0.20 |
Transplant effects | Worry about the transplan (TxEQb) | 14 | 3.4 (2.5–4.0) | 16 | 3.1 (2.6–3.5) | 29 | 3.3 (2.7–3.7) | 0.69 | 0.69 | 0.11 | 0.48 |
Transplant effects | Guilt towards the donor (TxEQb) | 16 | 2.1 (1.8–2.6) | 16 | 2.0 (1.6–2.2) | 33 | 2.2 (1.8–2.8) | 0.08 | 0.07 | 0.54 | 0.34 |
Transplant effects | Disclosure about the transplantation (TxEQb) | 16 | 5.0 (4.0–5.0) | 16 | 4.8 (4.4–5.0) | 32 | 4.8 (3.7–5.0) | 0.85 | 0.07 | − 0.01 | 0.31 |
Transplant effects | Adherence to immunosuppressive medications (TxEQb) | 16 | 4.8 (4.4–5.0) | 16 | 5.0 (4.6–5.0) | 32 | 4.8 (4.1–5.0) | 0.03 | 0.12 | 0.81 | 0.43 |
Transplant effects | Responsibility towards others (TxEQb) | 16 | 3.5 (3.0–4.0) | 16 | 3.6 (3.3–4.0) | 33 | 3.8 (3.0–4.3) | 0.86 | 0.36 | 0.02 | 0.20 |
Social support | Social integration and support (heiQb) | 16 | 18.5 (13.5–20.0) | 16 | 19.0 (15.0–20.0) | 33 | 18.0 (15.0–20.0) | 0.78 | 0.91 | − 0.09 | −0.04 |
Patient-centred care | Total score (CAHPSb) | 15 | 19.0 (18.0–20.0) | 15 | 20.0 (20.0–20.0) | 32 | 19.5 (18.0–20.0) | 0.05 | 0.02 | 0.56 | 0.56 |